Low level light therapy for the treatment of recalcitrant chalazia: a sample case summary
Received 31 July 2019
Accepted for publication 29 August 2019
Published 5 September 2019 Volume 2019:13 Pages 1727—1733
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Karl Stonecipher,1 Richard Potvin2
1Physicians Protocol, Greensboro, NC, USA; 2Science in Vision, Akron, NY, USA
Correspondence: Karl Stonecipher
Physicians Protocol, 1002 North Church Street, Suite 101, Greensboro, NC 27408, USA
Tel +1 336 288 8823
Purpose: To evaluate the effects of low-level light therapy (LLLT) on the resolution of recalcitrant chalazia.
Patients and Methods: This was a single-site retrospective chart review of patients with chalazia, all of whom were unresponsive to previous pharmaceutical therapy or surgical intervention, who received a 15 min LLLT treatment in conjunction with a standard pharmaceutical regimen. A second treatment was applied 24 hrs to as late as 2 months if there was no evidence of progression of resolution in appearance.
Results: A total of 26 eyes of 22 patients with relevant history and treatment were reviewed, all with a history of prior pharmaceutical treatment for their chalazia. After a single 15 min LLLT treatment, followed by a standard pharmaceutical regimen, 46% of eyes (12/26) showed resolution of their chalazia. Resolution was noted from 3 days to one-month post-treatment. With a second treatment, the chalazia resolved in 92% of eyes (24/26). Only two eyes of the 26 (8%) required incision and curettage after LLLT treatment.
Conclusion: The use of LLLT for the treatment of recalcitrant chalazia appears to be beneficial in patients who have failed topical and/or systemic therapy, significantly reducing the likelihood of requiring surgical intervention.
Keywords: LLLT, low level light therapy, chalazion, chalazia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]